Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. (15th August 2017)

• Record Type: Journal Article
• Authors: Korompoki, Eleni; Filippidis, Filippos T.; Nielsen, Peter B.; Del Giudice, Angela; Lip, Gregory Y. H.; Kuramatsu, Joji B.; Huttner, Hagen B.; Fang, Jiming; Schulman, Sam; Martí-Fàbregas, Joan; Gathier, Celine S.; Viswanathan, Anand; Biffi, Alessandro; Poli, Daniela; Weimar, Christian; Malzahn, Uwe; Heuschmann, Peter; Veltkamp, Roland
• Is Part Of: Neurology. Volume 89:Number 7(2017)
• Publication Date: 2017-08-15
• Subjects: Neurology -- Periodicals; Neurology -- Periodicals; Neurologie -- Périodiques; 616.8
• DOI: 10.1212/WNL.0000000000004235
• Languages: English
• ISSNs: 0028-3878

Abstract

Abstract : Objective: To perform a systematic review and meta-analysis of studies reporting recurrent intracranial hemorrhage (ICH) and ischemic stroke (IS) in ICH survivors with atrial fibrillation (AF) during long-term follow-up. Methods: A comprehensive literature search including MEDLINE, EMBASE, Cochrane library, clinical trials registry was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. We considered studies capturing outcome events (ICH recurrence and IS) for ≥3 months and treatment exposure to vitamin K antagonists (VKAs), antiplatelet agents (APAs), or no antithrombotic medication (no-ATM). Corresponding authors provided aggregate data for IS and ICH recurrence rate between 6 weeks after the event and 1 year of follow-up for each treatment exposure. Meta-analyses of pooled rate ratios (RRs) were conducted with the inverse variance method. Results: Seventeen articles met inclusion criteria. Seven observational studies enrolling 2, 452 patients were included in the meta-analysis. Pooled RR estimates for IS were lower for VKAs compared to APAs (RR = 0.45, 95% confidence interval [CI] 0.27–0.74, p = 0.002) and no-ATM (RR = 0.47, 95% CI 0.29–0.77, p = 0.002). Pooled RR estimates for ICH recurrence were not significantly increased across treatment groups (VKA vs APA: RR = 1.34, 95% CI 0.79–2.30, p = 0.28; VKA vs no-ATM: RR = 0.93, 95% CI 0.45–1.90, p = 0.84). Conclusions: In observational studies, anticoagulation with VKA is associated with a lower rate of IS than APA or no-ATM without increasing ICH recurrence significantly. A randomized controlled trial is needed to determine the net clinical benefit of anticoagulation in ICH survivors with AF.